ON 01910.Na inhibits growth of diffuse large B-cell lymphoma by cytoplasmic sequestration of sumoylated C-MYB/TRAF6 complex

Translational Research

Volumn 175, Issue , 2016, Pages 129-143.e13

  Dai, Yi Han ^a   Hung, Liang Yi ^b   Chen, Ruo Yu ^b   Lai, Chien Hsien ^b   Chang, Kung Chao ^a,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN C MYB; PROTEIN UBC9; RAN GTPASE ACTIVATING PROTEIN 1; RIGOSERTIB; SUMO 1 PROTEIN; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; TUMOR PROTEIN; UNCLASSIFIED DRUG; GLYCINE; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; RANGAP1 PROTEIN, HUMAN; SULFONE; UBIQUITIN CONJUGATING ENZYME; UBIQUITIN-CONJUGATING ENZYME UBC9;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER GROWTH; CANCER PROGNOSIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; DIFFUSE LARGE B CELL LYMPHOMA; DRUG EFFICACY; FEMALE; HT CELL LINE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; IMMUNOPRECIPITATION; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; SU-DHL-5 CELL LINE; SUMOYLATION; TUMOR REGRESSION; TUMOR XENOGRAFT; U-2932 CELL LINE; U-2940 CELL LINE; ANALOGS AND DERIVATIVES; ANIMAL; BIOLOGICAL MODEL; CELL CYCLE CHECKPOINT; CELL DEATH; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; DRUG EFFECTS; FLUORESCENT ANTIBODY TECHNIQUE; GENE SILENCING; LYMPHOMA, LARGE B-CELL, DIFFUSE; METABOLISM; NONOBESE DIABETIC MOUSE; PATHOLOGY; PHOSPHORYLATION; PROGNOSIS; SCID MOUSE; TUMOR CELL LINE;

ANIMALS; CELL CYCLE CHECKPOINTS; CELL DEATH; CELL LINE, TUMOR; CELL NUCLEUS; CELL PROLIFERATION; CYTOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; GENE KNOCKDOWN TECHNIQUES; GLYCINE; GTPASE-ACTIVATING PROTEINS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MICE, INBRED NOD; MICE, SCID; MODELS, BIOLOGICAL; PHOSPHORYLATION; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MYB; SULFONES; SUMOYLATION; TNF RECEPTOR-ASSOCIATED FACTOR 6; UBIQUITIN-CONJUGATING ENZYMES;

EID: 84970028060     PISSN: 19315244     EISSN: 18781810     Source Type: Journal    
DOI: 10.1016/j.trsl.2016.04.001     Document Type: Article

References (51)

1. Swerdlow, S.H., Campo, E., Harris, N.L., et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. 2008, IARC, Lyon, 233–237.
2. Chang, K.C., Huang, G.C., Jones, D., et al. Distribution and prognosis of WHO lymphoma subtypes in Taiwan reveals a low incidence of germinal-center derived tumors. Leuk Lymphoma 45 (2004), 1375–1384.
3. Coiffier, B., Lepage, E., Briere, J., et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346 (2002), 235–242.
4. Pfreundschuh, M., How I treat elderly patients with diffuse large B-cell lymphoma. Blood 116 (2010), 5103–5110.
5. Friedberg, J.W., Relapsed/refractory diffuse large B-cell lymphoma. Hematology Am Soc Hematol Educ Program 2011 (2011), 498–505.
6. Roschewski, M., Dunleavy, K., Wilson, W.H., Diffuse large B cell lymphoma: molecular targeted therapy. Int J Hematol 96 (2012), 552–561.
7. Roschewski, M., Staudt, L.M., Wilson, W.H., Diffuse large B-cell lymphoma-treatment approaches in the molecular era. Nat Rev Clin Oncol 11 (2014), 12–23.
8. Kaneko, N., Mitsuoka, K., Amino, N., et al. Combination of YM155, a survivin suppressant, with bendamustine and rituximab: a new combination therapy to treat relapsed/refractory diffuse large B-cell lymphoma. Clin Cancer Res 20 (2014), 1814–1822.
9. Nicolaides, N.C., Gualdi, R., Casadevall, C., Manzella, L., Calabretta, B., Positive autoregulation of c-myb expression via Myb binding sites in the 5’ flanking region of the human c-myb gene. Mol Cell Biol 11 (1991), 6166–6176.
10. Pham, L.V., Zhou, H.J., Lin-Lee, Y.C., et al. Nuclear tumor necrosis factor receptor-associated factor 6 in lymphoid cells negatively regulates c-Myb-mediated transactivation through small ubiquitin-related modifier-1 modification. J Biol Chem 283 (2008), 5081–5089.
11. Pattabiraman, D.R., Gonda, T.J., Role and potential for therapeutic targeting of MYB in leukemia. Leukemia 27 (2013), 269–277.
12. Ramsay, R.G., Gonda, T.J., MYB function in normal and cancer cells. Nat Rev Cancer 8 (2008), 523–534.
13. Gill, G., Something about SUMO inhibits transcription. Curr Opin Genet Dev 15 (2005), 536–541.
14. Streubel, G., Bouchard, C., Berberich, H., et al. PRMT4 is a novel coactivator of c-Myb-dependent transcription in haematopoietic cell lines. PLoS Genet, 9, 2013, e1003343.
15. Thomas, M.D., Kremer, C.S., Ravichandran, K.S., Rajewsky, K., Bender, T.P., c-Myb is critical for B cell development and maintenance of follicular B cells. Immunity 23 (2005), 275–286.
16. Baron, B.W., Anastasi, J., Bies, J., et al. GFI1B, EVI5, MYB–additional genes that cooperate with the human BCL6 gene to promote the development of lymphomas. Blood Cells Mol Dis 52 (2014), 68–75.
17. Emambokus, N., Vegiopoulos, A., Harman, B., et al. Progression through key stages of haemopoiesis is dependent on distinct threshold levels of c-Myb. EMBO J 22 (2003), 4478–4488.
18. Fang, J., Rhyasen, G., Bolanos, L., et al. Cytotoxic effects of bortezomib in myelodysplastic syndrome/acute myeloid leukemia depend on autophagy-mediated lysosomal degradation of TRAF6 and repression of PSMA1. Blood 120 (2012), 858–867.
19. Sun, H., Li, X.B., Meng, Y., et al. TRAF6 upregulates expression of HIF-1alpha and promotes tumor angiogenesis. Cancer Res 73 (2013), 4950–4959.
20. Meng, Q., Zheng, M., Liu, H., et al. TRAF6 regulates proliferation, apoptosis, and invasion of osteosarcoma cell. Mol Cell Biochem 371 (2012), 177–186.
21. Zhong, L., Cao, F., You, Q., Effect of TRAF6 on the biological behavior of human lung adenocarcinoma cell. Tumour Biol 34 (2013), 231–239.
22. Inoue, J., Gohda, J., Akiyama, T., Semba, K., NF-kappaB activation in development and progression of cancer. Cancer Sci 98 (2007), 268–274.
23. Liu, H., Tamashiro, S., Baritaki, S., et al. TRAF6 activation in multiple myeloma: a potential therapeutic target. Clin Lymphoma Myeloma Leuk 12 (2012), 155–163.
24. Paik, J.H., Jang, J.Y., Jeon, Y.K., et al. MicroRNA-146a downregulates NFkappaB activity via targeting TRAF6 and functions as a tumor suppressor having strong prognostic implications in NK/T cell lymphoma. Clin Cancer Res 17 (2011), 4761–4771.
25. Chang, K.C., Chang, W.C., Chang, Y., et al. Ran GTPase-activating protein 1 is a therapeutic target in diffuse large B-cell lymphoma. PLoS One, 8, 2013, e79863.
26. Gumireddy, K., Reddy, M.V., Cosenza, S.C., et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plk1, is a potent anticancer agent. Cancer Cell 7 (2005), 275–286.
27. Chapman, C.M., Sun, X., Roschewski, M., et al. ON 01910.Na is selectively cytotoxic for chronic lymphocytic leukemia cells through a dual mechanism of action involving PI3K/AKT inhibition and induction of oxidative stress. Clin Cancer Res 18 (2012), 1979–1991.
28. Jimeno, A., Li, J., Messersmith, W.A., et al. Phase I study of ON 01910.Na, a novel modulator of the Polo-like kinase 1 pathway, in adult patients with solid tumors. J Clin Oncol 26 (2008), 5504–5510.
29. Prasad, A., Park, I.W., Allen, H., et al. Styryl sulfonyl compounds inhibit translation of cyclin D1 in mantle cell lymphoma cells. Oncogene 28 (2009), 1518–1528.
30. Xu, F., He, Q., Li, X., et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep, 4, 2014, 7310.
31. Silverman, L.R., Greenberg, P., Raza, A., et al. Clinical activity and safety of the dual pathway inhibitor rigosertib for higher risk myelodysplastic syndromes following DNA methyltransferase inhibitor therapy. Hematol Oncol 33 (2015), 57–66.
32. Chenevix-Trench, G., Kerr, B., Walters, M., Lymphoblastoid cell lines from frozen whole blood: a quick and economical safeguard for linkage analysis. Am J Hum Genet 46 (1990), 635–636.
33. Chang, Y., Tung, C.H., Huang, Y.T., et al. Requirement for cell-to-cell contact in Epstein-Barr virus infection of nasopharyngeal carcinoma cells and keratinocytes. J Virol 73 (1999), 8857–8866.
34. Simbulan-Rosenthal, C.M., Rosenthal, D.S., Iyer, S., Boulares, A.H., Smulson, M.E., Transient poly(ADP-ribosyl)ation of nuclear proteins and role of poly(ADP-ribose) polymerase in the early stages of apoptosis. J Biol Chem 273 (1998), 13703–13712.
35. Truksa, J., Lee, P., Beutler, E., Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness. Blood 113 (2009), 688–695.
36. Chang, K.C., Chang, Y., Jones, D., Su, I.J., Aberrant expression of cyclin A correlates with morphogenesis of Reed-Sternberg cells in Hodgkin lymphoma. Am J Clin Pathol 132 (2009), 50–59.
37. Morita, Y., Kanei-Ishii, C., Nomura, T., Ishii, S., TRAF7 sequesters c-Myb to the cytoplasm by stimulating its sumoylation. Mol Biol Cell 16 (2005), 5433–5444.
38. Reddy, M.V., Mallireddigari, M.R., Cosenza, S.C., et al. Design, synthesis, and biological evaluation of (E)-styrylbenzylsulfones as novel anticancer agents. J Med Chem 51 (2008), 86–100.
39. Preda, A., Ohnuma, T., Jiang, J.D., Holland, J.F., Reddy, E.P., Cross-resistance to ON01910. Na among drug-resistant human tumor cell lines. Cancer Res, 66(8 Suppl), 2006, 1106.
40. Agoni, L., Basu, I., Gupta, S., et al. Rigosertib is a more effective radiosensitizer than cisplatin in concurrent chemoradiation treatment of cervical carcinoma, in vitro and in vivo. Int J Radiat Oncol Biol Phys 88 (2014), 1180–1187.
41. Roschewski, M., Farooqui, M., Aue, G., Wilhelm, F., Wiestner, A., Phase I study of ON 01910.Na (Rigosertib), a multikinase PI3K inhibitor in relapsed/refractory B-cell malignancies. Leukemia 27 (2013), 1920–1923.
42. Werner, A., Flotho, A., Melchior, F., The RanBP2/RanGAP1*SUMO1/Ubc9 complex is a multisubunit SUMO E3 ligase. Mol Cell 46 (2012), 287–298.
43. Nakagoshi, H., Kanei-Ishii, C., Sawazaki, T., Mizuguchi, G., Ishii, S., Transcriptional activation of the c-myc gene by the c-myb and B-myb gene products. Oncogene 7 (1992), 1233–1240.
44. Davidson, C.J., Guthrie, E.E., Lipsick, J.S., Duplication and maintenance of the Myb genes of vertebrate animals. Biol Open 2 (2013), 101–110.
45. Huang, Y., Jiang, Y., Lu, W., Zhang, Y., Nemo-like kinase associated with proliferation and apoptosis by c-Myb degradation in breast cancer. PLoS One, 8, 2013, e69148.
46. Zhou, F., Zhang, L., van Laar, T., van Dam, H., Ten Dijke, P., GSK3beta inactivation induces apoptosis of leukemia cells by repressing the function of c-Myb. Mol Biol Cell 22 (2011), 3533–3540.
47. Park, Y.J., Lee, J.M., Lee, M.S., Kim, Y.H., Shin, S.Y., c-Myb negatively regulates Ras signaling through induction of dual phosphatase MKP-3 in NIH3T3 cells. Biochem Biophys Res Commun 450 (2014), 1032–1037.
48. Fu, L., Lin-Lee, Y.C., Pham, L.V., et al. Constitutive NF-kappaB and NFAT activation leads to stimulation of the BLyS survival pathway in aggressive B-cell lymphomas. Blood 107 (2006), 4540–4548.
49. Mozos, A., Roue, G., Lopez-Guillermo, A., et al. The expression of the endoplasmic reticulum stress sensor BiP/GRP78 predicts response to chemotherapy and determines the efficacy of proteasome inhibitors in diffuse large B-cell lymphoma. Am J Pathol 179 (2011), 2601–2610.
50. Sarvaiya, P.J., Schwartz, J.R., Hernandez, C.P., Rodriguez, P.C., Vedeckis, W.V., Role of c-Myb in the survival of pre B-cell acute lymphoblastic leukemia and leukemogenesis. Am J Hematol 87 (2012), 969–976.
51. Hyoda, T., Tsujioka, T., Nakahara, T., et al. Rigosertib induces cell death of a myelodysplastic syndrome-derived cell line by DNA damage-induced G2/M arrest. Cancer Sci 106 (2015), 287–293.